

August 30, 2024

The Secretary,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
C/1 G Block, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
(Scrip Code: **THYROCARE**)

The Secretary,
Listing Department,
BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001
(Scrip Code: **539871**)

Dear Sir/Madam,

Subject: Intimation regarding execution of Business Transfer Agreement (“BTA”) with Vimta Labs Limited.

Dear Sir/Madam,

This is to inform you that the Company has entered into Business Transfer Agreement (“BTA”) on August 30, 2024, around 11.00 am with, Vimta Labs Limited (“Vimta”), by which the Company would be acquiring Vimta’s diagnostic and pathological services business as a going concern (on a slump sale basis). Completion of the said acquisition is subject to fulfilment of the Conditions Precedent (“CP”).

Details required under Regulation 30 of the Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are given in the Disclosure Sheet attached as Annexure - 1 to this Letter.

Yours Faithfully,
For **Thyrocare Technologies Limited**

Ramjee Dorai
Company Secretary and Compliance officer

Encl: A/a

Annexure 1

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sr	Particulars	Disclosures
1	Name of the target entity, details in brief such as size, turnover, etc;	<p>Not applicable as no entity is being acquired, as such.</p> <p>Details of the transaction:</p> <p>The proposed transaction envisages our Company's (TTL's) acquisition and purchase of Vimta's diagnostic and pathological services business, hitherto being carried on by Vimta, on a 'slump sale' basis as a 'going concern', as per the terms and conditions of the BTA and other documents / agreements executed/to be executed in this regard (collectively, the "Definitive Agreements").</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length	No
3	Industry to which the entity being acquired belongs;	<p>No entity, as such, is being acquired.</p> <p>The diagnostic and pathological services business of Vimta which is being acquired, was engaged in the business of providing clinical diagnostics and pathological services (excluding clinical research studies) to its business-to-business customers and certain direct walk-in customers, through its laboratories in various states, including sample collection and sample processing for such customers.</p>
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity	<p>The Company aims to expand its diagnostic and pathological services business further through this acquisition.</p> <p>This strategic move aligns with the Company's growth objectives, allowing to expand its market share, solidify the leadership position of the Company in South India, and grow the Company's business with franchisees and hospitals.</p> <p>Additionally, this expansion will enable Thyrocare to leverage the benefits of scale.</p>

5	Brief details of any governmental or regulatory approvals required for the acquisition	No governmental or regulatory approvals are required for this acquisition.
6	Indicative time period for completion of the acquisition	Completion of the acquisition is subject to fulfilment of the Conditions Precedent (“CP”).
7	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration.
8	Cost of acquisition or the price at which the shares are acquired	Purchase consideration for acquiring diagnostic and pathological services business of Vimta is INR 7 crores.
9	Percentage of shareholding / control acquired and / or number of shares acquired	Not applicable as no acquisition of control/ shares/voting rights is being contemplated
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information	Not applicable as no acquisition of any entity, as such, is envisaged.